Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Conditions

Squamous Cell Carcinoma of Head and Neck 4Neoplasms 3Neoplasms by Site 2Neoplasms by Histologic Type 2Neoplasm Metastasis 2Leukemia, Myeloid, Acute 2Carcinoma, Squamous Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Vascular Diseases 1Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Recurrence 1Pathologic Processes 1Paraproteinemias 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplastic Processes 1Neoplasms, Plasma Cell 1Neoplasms, Glandular and Epithelial 1Multiple Myeloma 1Mullerian Mixed Tumor of Ovary 1Mouth Neoplasms 1Lymphoproliferative Disorders 1Lymphoma 1Lymphoid Interstitial Pneumonia 1Lymphatic Diseases 1Lung Neoplasms 1Lung Diseases 1

Interventions

ficlatuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mullerian Mixed Tumor of Ovary × ficlatuzumab × Clear all
NCT02090127 2015-07-29

Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient

AVEO Pharmaceuticals, Inc.

No longer available

Mullerian Mixed Tumor of Ovary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡